We explored the associations between lipoprotein-associated phospholipase A2 (Lp-PLA2) level and carotid atherosclerosis with all phenotypes and cardiovascular disease (CVD) events in Chinese older adults. A total of 1257 adults aged ≥55 years who were free of CVD were enrolled in this cohort study. Lipoprotein-associated phospholipase A2 level was evaluated in 3 categories: Lp-PLA2 < 175, 175≤ Lp-PLA2 < 223, and Lp-PLA2 ≥ 223 ng/mL. The highest level of Lp-PLA2 was independently associated with common carotid artery intima-media thickening (≥1.0 mm; odds ratio [OR]: 1.60, 95% confidence interval [CI]: 1.14-2.26) and carotid plaque (OR: 1.42, 95% CI: 1.01-1.99) in individuals without carotid artery stenosis. At the end of the 5-year follow-up, after adjustment for CVD risk factors and carotid atherosclerosis status, Lp-PLA2 had remained an independent predictor for myocardial infarction (MI; hazard ratio [HR]: 1.90, 95% CI: 1.02-3.55) and CVD death (HR: 1.78, 95% CI: 1.02-3.13). However, no association was found with stroke. Therefore, elevated Lp-PLA2 level in the older adults studied was associated with an increased risk of carotid atherosclerosis and MI and CVD mortality. Lipoprotein-associated phospholipase A2 assessment might be used for MI and CVD death risk prediction.
WangWZhuMWangY, et al.Cardiovascular disease has become a public health issue in China—the summary of China cardiovascular disease report 2011. Chin Circ J. 2012;27(6):409–411.
2.
ZhouMWangHZhuJ, et al.Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet. 2016;387(10015):251–272.
3.
MachF. Inflammation is a crucial feature of atherosclerosis and a potential target to reduce cardiovascular events. Handb Exp Pharmacol. 2005;(170):697–722.
4.
TuttolomondoADi RaimondoDPecoraroRArnaoVPintoALicataG. Atherosclerosis as an inflammatory disease. Curr Pharm Des. 2012;18(28):4266–4288.
5.
GuXHouJYangS, et al.Is lipoprotein-associated phospholipase A2 activity correlated with fibrous-cap thickness and plaque volume in patients with acute coronary syndrome?Coron Artery Dis. 2014;25(1):10–15.
6.
RossR. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340(2):115–126.
7.
MadjidMWillersonJT. Inflammatory markers in coronary heart disease. Br Med Bull. 2011;100:23–38.
8.
VasanRSSullivanLMRoubenoffR, et al; Framingham Heart Study. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107(11):1486–1491.
9.
CesariMPenninxBWNewmanAB, et al.Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003;108(19):2317–2322.
10.
ZalewskiANelsonJJHeggLMacpheeC. Lp-PLA2: a new kid on the block. Clin Chem. 2006;52(9):1645–1650.
11.
ThompsonAGaoPOrfeiL, et al; Lp-PLA(2) Studies Collaboration. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375(9725):1536–1544.
12.
JennyNSSolomonCCushmanM, et al.Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study. Atherosclerosis. 2010;209(2):528–532.
13.
SuzukiTSolomonCJennyNS, et al.Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study. Circ Heart Fail. 2009;2(5):429–436.
14.
PackardCJO’ReillyDSCaslakeMJ, et al.Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343(16):1148–1155.
15.
SerruysPWGarcia-GarciaHMBuszmanP, et al; Integrated Biomarker and Imaging Study-2 Investigators. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008;118(11):1172–1182.
16.
UeshimaHKadowakiTHisamatsuT, et al; ACCESS and SESSA Research Groups. Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population. Atherosclerosis. 2016;246:141–147.
17.
WangCSongXMitnitskiA, et al.Effect of health protective factors on health deficit accumulation and mortality risk in older adults in the Beijing Longitudinal Study of Aging. J Am Geriatr Soc. 2014;62(5):821–828.
18.
GuXFangXHuaY, et al.Association between kidney dysfunction and carotid atherosclerosis in community-based older adults in China. Angiology. 2016;67(3):252–258.
19.
ZhangZFangXHuaY, et al.Combined effect of hyperhomocysteinemia and hypertension on the presence of early carotid artery atherosclerosis. J Stroke Cerebrovasc Dis. 2016;25(5):1254–1262.
20.
ChobanianAVBakrisGLBlackHR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–2572.
21.
American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care. 2011;34(suppl 1):S11–S61.
22.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421.
23.
SongDLiCWangX. Diagnosis and evaluation of coronary heart disease by lipoprotein associated phospholipase A2 in a Chinese Han population. Acta Acad Med CAPF. 2012;21(4):241–244.
24.
JellingerPSSmithDAMehtaAE, et al.American Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2012;18(supp1 1):1–78.
25.
TouboulPJHennericiMGMeairsS, et al.Mannheim carotid intima-media thickness consensus (2004-2006): an update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis. 2007;23(1):75–80.
26.
TouboulPJHennericiMGMeairsS, et al.Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis. 2012;34(4):290–296.
27.
KernRSzaboKHennericiMMeairsS. Characterization of carotid artery plaques using real-time compound B-mode ultrasound. Stroke. 2004;35(4):870–875.
28.
JoakimsenOBonaaKHStensland-BuggeE. Reproducibility of ultrasound assessment of carotid plaque occurrence, thickness, and morphology. The Tromso Study. Stroke. 1997;28(11):2201–2207.
29.
GrantEGBensonCBMonetaGL, et al; Society of Radiologists in Ultrasound. Carotid artery stenosis: grayscale and Doppler ultrasound diagnosis—Society of Radiologists in Ultrasound consensus conference. Ultrasound Q. 2003;19(4):190–198.
30.
ConstantinidesAvan PeltLJvan LeeuwenJJ, et al.Carotid intima media thickness is associated with plasma lipoprotein-associated phospholipase A2 mass in nondiabetic subjects but not in patients with type 2 diabetes. Eur J Clin Invest. 2011;41(8):820–827.
31.
KatanMMoonYPPaikMCWolfertRLSaccoRLElkindMS. Lipoprotein-associated phospholipase A2 is associated with atherosclerotic stroke risk: the Northern Manhattan Study. PLoS One. 2014;9(1):e83393
32.
KiortsisDNTsouliSLouridaES, et al.Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia. Angiology. 2005;56(4):451–458.
33.
PokharelYNambiVMartinSS, et al.Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players. Atherosclerosis. 2014;236(2):251–256.
34.
YamamotoIFujitsuJNohnenS, et al.Association of plasma PAF acetylhydrolase gene polymorphism with IMT of carotid arteries in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2003;59(3):219–224.
35.
ShiYZhangPZhangL, et al.Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis. 2007;191(1):54–62.
36.
WilenskyRLShiYMohlerER III, et al.Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med. 2008;14(10):1059–1066.
37.
KolodgieFDBurkeAPSkorijaKS, et al.Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26(11):2523–2529.
38.
GongHPDuYMZhongLN, et al.Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis. Lipids Health Dis. 2011;10:13.
39.
PokharelYSunWPolfusLM, et al.Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: the Atherosclerosis Risk In Communities Study. Atherosclerosis. 2015;241(2):641–648.
40.
DanielsLBLaughlinGASarnoMJBettencourtRWolfertRLBarrett-ConnorE. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J Am Coll Cardiol. 2008;51(9):913–919.
41.
BallantyneCMHoogeveenRCBangH, et al.Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005;165(21):2479–2484.
42.
WhiteHDHeldCStewartR, et al; STABILITY Investigators. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370(18):1702–1711.
43.
O’DonoghueMLBraunwaldEWhiteHD, et al; SOLID-TIMI 52 Investigators. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014;312(10):1006–1015.
